Select publications

Bolla M et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 2002;360(9327):103-6. Abstract

Eisenberger MA et al. A multicenter phase III comparison of docetaxel (D) + prednisone (P) and mitoxantrone (MTZ) + P in patients with hormone-refractory prostate cancer (HRPC). Proc ASCO 2004;Abstract 4.

Hanks GE et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003;21(21):3972-8. Abstract

Iversen P et al. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median follow-up from the Scandinavian Prostate Cancer Group Study Number 6. J Urol 2004;172(5 Pt 1):1871-6. Abstract

Lane TM et al. Long-term outcomes in patients with prostate cancer managed with intermittent androgen suppression. Urol Int 2004;73(2):117-22. Abstract

Lawton CA et al. Androgen suppression plus radiation versus radiation alone for patients with stage d1/pathologic node-positive adenocarcinoma of the prostate: Updated results based on national prospective randomized trial radiation therapy oncology group 85-31. J Clin Oncol 2005;23(4):800-7. Abstract

Messing EM et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341(24):1781-8. Abstract

Petrylak DP et al. SWOG 99-16: Randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone (M)/prednisone (p) in men with androgen-independent prostate cancer (AIPCA). Proc ASCO 2004;Abstract 3.

Wirth MP et al. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: Results from the second analysis of the early prostate cancer program at median follow-up of 5.4 years. J Urol 2004;172(5 Pt 1):1865-70. Abstract